April 2024
1. DE SOUZA IC, Langer FW
   Post-radiation angiosarcoma of the breast in a patient with a history of invasive ductal carcinoma.
   Lancet. 2024;403:1681-1682.
   

   >> Share

   
   
2. EARL HM
   Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
   Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
   

   >> Share

   
   
3. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
   3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
   Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
   

   >> Share

   
   March 2024
4. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
   Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
   Lancet. 2024;403:1240.
   

   >> Share

   
   
5. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
   Benefits and risks of anthracyclines in early-stage breast cancer.
   Lancet. 2024;403:1239-1240.
   

   >> Share

   
   
6. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
   Behcet's syndrome.
   Lancet. 2024;403:1093-1108.
   

   >> Share

   
   
7. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
   Managing menopause after cancer.
   Lancet. 2024;403:984-996.
   

   >> Share

   
   February 2024
8. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
   Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
   Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
   

   >> Share

   
   
9. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
   Diagnosis and management of ANCA-associated vasculitis.
   Lancet. 2024;403:683-698.
   

   >> Share

   
   
10. KIMBALL AB, Ravichandran S
    Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
    Lancet. 2024;403:617-618.
    

    >> Share

    
    
11. ENDO M, Kami M
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:617.
    

    >> Share

    
    
12. MAUL JT, Kolios AGA, Thomsen SF, Ring HC, et al
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:616-617.
    

    >> Share

    
    January 2024
13. BAKKER T, Klopotowska JE, Dongelmans DA, Eslami S, et al
    The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial.
    Lancet. 2024 Jan 19:S0140-6736(23)02465-0. doi: 10.1016/S0140-6736(23)02465.
    

    >> Share

    
    
14. WEBER JS, Carlino MS, Khattak A, Meniawy T, et al
    Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
    Lancet. 2024 Jan 18:S0140-6736(23)02268-7. doi: 10.1016/S0140-6736(23)02268.
    

    >> Share

    
    
15. MAURER M, Ensina LF, Gimenez-Arnau AM, Sussman G, et al
    Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Lancet. 2024;403:147-159.
    

    >> Share

    
    
16. MOUSSA S, Netchiporouk E
    Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
    Lancet. 2024;403:118-119.
    

    >> Share

    
    December 2023
17. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    

    >> Share

    
    
18. BRAUNSTEIN LZ
    Optimising adjuvant breast radiotherapy via preoperative imaging.
    Lancet. 2023 Dec 5:S0140-6736(23)02698-3. doi: 10.1016/S0140-6736(23)02698.
    

    >> Share

    
    
19. MANN GB, Skandarajah AR, Zdenkowski N, Hughes J, et al
    Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.
    Lancet. 2023 Dec 5:S0140-6736(23)02476-5. doi: 10.1016/S0140-6736(23)02476.
    

    >> Share

    
    November 2023
20. SAKAI K, Miyamori D
    Hyperviscosity syndrome caused by cryoglobulinemia diagnosed by observing the reversible formation of gel upon cooling and warming the patient's serum.
    Lancet. 2023;402:1866.
    

    >> Share

    
    
21. DEVJANI S, Engel PV, Javadi SS, Smith B, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis.
    Lancet. 2023;402:1833-1834.
    

    >> Share

    
    
22. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply.
    Lancet. 2023;402:1834.
    

    >> Share

    
    
23. 
    Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.
    Lancet. 2023 Nov 3:S0140-6736(23)01082-6. doi: 10.1016/S0140-6736(23)01082.
    

    >> Share

    
    
24. LEVINE MN
    Effective and safe regional node irradiation in early breast cancer.
    Lancet. 2023 Nov 3:S0140-6736(23)01614-8. doi: 10.1016/S0140-6736(23)01614.
    

    >> Share

    
    
25. ZAMAN M, de Vale ML, Coultas C, Goff L, et al
    Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach.
    Lancet. 2023;402 Suppl 1:S96.
    

    >> Share

    
    
26. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    

    >> Share

    
    
27. HUNTLEY C, Torr B, Sud A, Houlston RS, et al
    The impact of risk stratification by polygenic risk and age on breast cancer screening in women aged 40-49 years: a modelling study.
    Lancet. 2023;402 Suppl 1:S54.
    

    >> Share

    
    
28. ACHARYA A, Darzi A, Judah G
    An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S17.
    

    >> Share

    
    October 2023
29. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    

    >> Share

    
    September 2023
30. HANOUNEH M, Arend LJ
    Ichthyosis in sarcoidosis: a rare skin manifestation of a systemic disease.
    Lancet. 2023;402:1083-1084.
    

    >> Share

    
    
31. JO SJ, Jaihyun Cho R
    Preventing generalised pustular psoriasis.
    Lancet. 2023 Sep 19:S0140-6736(23)01480-0. doi: 10.1016/S0140-6736(23)01480.
    

    >> Share

    
    
32. MORITA A, Strober B, Burden AD, Choon SE, et al
    Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
    Lancet. 2023 Sep 19:S0140-6736(23)01378-8. doi: 10.1016/S0140-6736(23)01378.
    

    >> Share

    
    
33. BECKER JC, Ugurel S, Leiter U, Meier F, et al
    Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
    Lancet. 2023;402:798-808.
    

    >> Share

    
    
34. SAIAG P, Blom A
    Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
    Lancet. 2023;402:751-753.
    

    >> Share

    
    
35. MANSFIELD BS, Raal FJ
    Regression of cutaneous xanthomata in patient with homozygous familial hypercholesterolemia using novel therapies.
    Lancet. 2023;402:e11.
    

    >> Share

    
    August 2023
36. RUGO HS, Bardia A, Marme F, Cortes J, et al
    Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Aug 23:S0140-6736(23)01245-X. doi: 10.1016/S0140-6736(23)01245.
    

    >> Share

    
    
37. THORNTON J
    Scabies in Cox's Bazar.
    Lancet. 2023;402:600.
    

    >> Share

    
    July 2023
38. LONG GV, Swetter SM, Menzies AM, Gershenwald JE, et al
    Cutaneous melanoma.
    Lancet. 2023 Jul 24:S0140-6736(23)00821-8. doi: 10.1016/S0140-6736(23)00821.
    

    >> Share

    
    June 2023
39. COLES CE, Haviland JS, Kirby AM, Griffin CL, et al
    Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
    Lancet. 2023 Jun 8:S0140-6736(23)00619-0. doi: 10.1016/S0140-6736(23)00619.
    

    >> Share

    
    April 2023
40. IQBAL M, Kharfan-Dabaja MA
    Cogent data on allogeneic haematopoietic stem-cell transplantation efficacy in advanced cutaneous T-cell lymphoma.
    Lancet. 2023 Apr 24:S0140-6736(23)00631-1. doi: 10.1016/S0140-6736(23)00631.
    

    >> Share

    
    
41. DE MASSON A, Beylot-Barry M, Ram-Wolff C, Mear JB, et al
    Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
    Lancet. 2023 Apr 24:S0140-6736(23)00329-X. doi: 10.1016/S0140-6736(23)00329.
    

    >> Share

    
    
42. HAKIMI M, North JP, Taylor MA, Hailer A, et al
    Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease.
    Lancet. 2023;401:1381.
    

    >> Share

    
    
43. ANDRE F, Hee Park Y, Kim SB, Takano T, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Apr 19:S0140-6736(23)00725-0. doi: 10.1016/S0140-6736(23)00725.
    

    >> Share

    
    
44. CHUMSRI S
    Advancing outcomes of metastatic HER2-positive breast cancer.
    Lancet. 2023 Apr 19:S0140-6736(23)00805-X. doi: 10.1016/S0140-6736(23)00805.
    

    >> Share

    
    
45. 
    Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    Lancet. 2023;401:1277-1292.
    

    >> Share

    
    
46. SHEN SJ, Liu CM
    Chemotherapy for early-stage breast cancer: the more the better?
    Lancet. 2023;401:1243-1245.
    

    >> Share

    
    
47. MULLER M, Ingold-Heppner B, Stocker H, Heppner FL, et al
    Skin lesion specimens as first choice to detect monkeypox virus - Authors' reply.
    Lancet. 2023;401:1265.
    

    >> Share

    
    
48. ZHOU YB
    Skin lesion specimens as first choice to detect monkeypox virus.
    Lancet. 2023;401:1264-1265.
    

    >> Share

    
    
49. KING B, Zhang X, Harcha WG, Szepietowski JC, et al
    Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
    Lancet. 2023 Apr 13:S0140-6736(23)00222-2. doi: 10.1016/S0140-6736(23)00222.
    

    >> Share

    
    
50. JAVAUD N, Gobert D
    Hereditary angioedema: is there a better future for treatment?
    Lancet. 2023;401:1054-1055.
    

    >> Share

    
    
51. CRAIG TJ, Reshef A, Li HH, Jacobs JS, et al
    Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023;401:1079-1090.
    

    >> Share

    
    March 2023
52. EGEBERG A, Thyssen JP
    The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered.
    Lancet. 2023;401:708-710.
    

    >> Share

    
    
53. KIMBALL AB, Jemec GBE, Alavi A, Reguiai Z, et al
    Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Lancet. 2023;401:747-761.
    

    >> Share

    
    February 2023
54. CORREA-SELM L, Hanlon KL, Grichnik JM
    Differentiating activated Langerhans cells and dendritic melanocytes using reflectance confocal microscopy: the limitations of diagnosing melanoma in vivo.
    Lancet. 2023;401:590.
    

    >> Share

    
    
55. AYGOREN-PURSUN E, Zanichelli A, Cohn DM, Cancian M, et al
    An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Lancet. 2023;401:458-469.
    

    >> Share

    
    
56. RESHEF A, Grumach AS
    New medications to mitigate attacks of hereditary angioedema: does one size fit all?
    Lancet. 2023;401:413-415.
    

    >> Share

    
    January 2023
57. VOLKMANN ER, Andreasson K, Smith V
    Systemic sclerosis.
    Lancet. 2023;401:304-318.
    

    >> Share

    
    
58. ZHOU YB
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed.
    Lancet. 2023;401:104.
    

    >> Share

    
    
59. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed - Authors' reply.
    Lancet. 2023;401:104.
    

    >> Share

    
    
60. CHUA BH, Link EK, Kunkler IH, Olivotto IA, et al
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.
    Lancet. 2023;401:24.
    

    >> Share

    
    
61. MULLIEZ T, De Ridder M
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?
    Lancet. 2023;401:23-24.
    

    >> Share

    
    
62. MEROLA JF, Landewe R, McInnes IB, Mease PJ, et al
    Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Lancet. 2023;401:38-48.
    

    >> Share

    
    
63. QUEIRO R
    Bimekizumab in psoriatic arthritis: a great leap forward?
    Lancet. 2023;401:2-3.
    

    >> Share

    
    
64. MCINNES IB, Asahina A, Coates LC, Landewe R, et al
    Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    Lancet. 2023;401:25-37.
    

    >> Share

    
    
65. MITJA O, Ogoina D, Titanji BK, Galvan C, et al
    Monkeypox.
    Lancet. 2023;401:60-74.
    

    >> Share

    
    December 2022
66. THYSSEN JP, Schmid-Grendelmeier P
    Long-term disease control in atopic dermatitis using biologics.
    Lancet. 2022 Dec 9:S0140-6736(22)02347-9. doi: 10.1016/S0140-6736(22)02347.
    

    >> Share

    
    
67. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Lancet. 2022 Dec 9:S0140-6736(22)02037-2. doi: 10.1016/S0140-6736(22)02037.
    

    >> Share

    
    
68. RASSY E, Delaloge S
    A second-generation antibody-drug conjugate to treat HER2-positive breast cancer.
    Lancet. 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534.
    

    >> Share

    
    
69. HURVITZ SA, Hegg R, Chung WP, Im SA, et al
    Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Lancet. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420.
    

    >> Share

    
    November 2022
70. SANCHEZ-MEZA E, Kubelis-Lopez DE, Ocampo-Candiani J, Chavez-Alvarez S, et al
    Prominent skin folds of the scalp provide a superficial clue in acromegaly.
    Lancet. 2022;400:1802.
    

    >> Share

    
    
71. VRSELJA A, Latifi A, Baber RJ, Stuckey BGA, et al
    Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1704-1711.
    

    >> Share

    
    
72. CRANDALL CJ, Ganz PA
    Phase 2 data on a new treatment for hot flushes in women with breast cancer.
    Lancet. 2022;400:1659-1661.
    

    >> Share

    
    October 2022
73. 
    Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial.
    Lancet. 2022;400:1334-1344.
    

    >> Share

    
    September 2022
74. KIM S, Wuthrick E, Blakaj D, Eroglu Z, et al
    Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Lancet. 2022;400:1008-1019.
    

    >> Share

    
    
75. SAIAG P, Blom A
    Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma.
    Lancet. 2022;400:976-977.
    

    >> Share

    
    
76. PALLER AS, Simpson EL, Siegfried EC, Cork MJ, et al
    Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2022;400:908-919.
    

    >> Share

    
    
77. HALLING AS, Thyssen JP
    Biological therapy for young children with atopic dermatitis.
    Lancet. 2022;400:867-869.
    

    >> Share

    
    
78. LIVINGSTONE E, Zimmer L, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01654.
    

    >> Share

    
    
79. SMITHY JW, Postow MA
    Adjuvant checkpoint blockade following complete local therapy for melanoma metastases.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01748.
    

    >> Share

    
    August 2022
80. DESCAMPS V
    DRESS syndrome.
    Lancet. 2022;400:560.
    

    >> Share

    
    
81. HINDIE E
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed?
    Lancet. 2022;400:559.
    

    >> Share

    
    
82. LUKE JJ, Ibrahim N, Eggermont AM
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply.
    Lancet. 2022;400:559-560.
    

    >> Share

    
    
83. CHUA BH, Link EK, Kunkler IH, Whelan TJ, et al
    Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
    Lancet. 2022;400:431-440.
    

    >> Share

    
    
84. COLES CE, Chatterjee S, Jagsi R, Kirby AM, et al
    Breast radiotherapy for ductal carcinoma in situ: could less be more?
    Lancet. 2022;400:408-410.
    

    >> Share

    
    July 2022
85. REICH K, Thyssen JP, Blauvelt A, Eyerich K, et al
    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Lancet. 2022;400:273-282.
    

    >> Share

    
    
86. MENNINI M, Di Nardo G, Fiocchi AG
    Atopic dermatitis: time for tailored therapy.
    Lancet. 2022;400:252-253.
    

    >> Share

    
    
87. RUDD EC, Kulasekararaj A, Basu TN
    Facial lymphoedema, viral warts, and myelodysplastic syndrome: the protean condition of GATA2 deficiency.
    Lancet. 2022;400:236.
    

    >> Share

    
    June 2022
88. SKJERVEN HO, Lie A, Vettukattil R, Rehbinder EM, et al
    Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2022;399:2398-2411.
    

    >> Share

    
    
89. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Sweet's syndrome and Crohn's disease diagnosed simultaneously.
    Lancet. 2022;399:2155.
    

    >> Share

    
    May 2022
90. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.
    

    >> Share

    
    
91. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    

    >> Share

    
    
92. ABDELNABI M, Elmssary M, Sekhon J, Benjanuwattra J, et al
    Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
    Lancet. 2022;399:1902.
    

    >> Share

    
    April 2022
93. MEGALY M, Boshra N
    Pyogenic granuloma-like Kaposi's sarcoma.
    Lancet. 2022;399:e38.
    

    >> Share

    
    
94. TCHERNEV G, Chokoeva AA
    Melanoma in a Chinese dragon tattoo.
    Lancet. 2022;399:e37.
    

    >> Share

    
    March 2022
95. LUKE JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al
    Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
    Lancet. 2022 Mar 31. pii: S0140-6736(22)00562.
    

    >> Share

    
    
96. DRIVENES JL, Betz RC, Bygum A
    A girl with unruly locks: molecular genetics makes a diagnosis of uncombable hair syndrome.
    Lancet. 2022;399:1079.
    

    >> Share

    
    
97. CRAIG T, Magerl M, Levy DS, Reshef A, et al
    Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2022;399:945-955.
    

    >> Share

    
    
98. FIJEN LM, Levi M
    Prophylaxis with anti-activated factor XII for hereditary angioedema.
    Lancet. 2022;399:889-890.
    

    >> Share

    
    February 2022
99. KUMAR A, Preston N, Phillips R
    Picturing health: Buruli ulcer in Ghana.
    Lancet. 2022;399:786-797.
    

    >> Share

    
    
100. COLES CE, Anderson BO, Cameron D, Cardoso F, et al
     The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
     Lancet. 2022 Feb 18. pii: S0140-6736(22)00184.
     

     >> Share

     
     December 2021
101. AL-MATAR SH, Sairam C, Roussel L, Langelier MJ, et al
     Fever, abdominal pain, serositis, arthralgia, hearing loss, proteinuria, and a family history: Muckle Wells syndrome.
     Lancet. 2021;398:2101.
     

     >> Share

     
     November 2021
102. MURPHY MJ, Damsky W, Vesely MD
     A pruritic psoriatic plaque develops at the donor site of an autologous skin graft: Koebner phenomenon.
     Lancet. 2021;398:1836.
     

     >> Share

     
     October 2021
103. GONZALES E, Hardikar W, Stormon M, Baker A, et al
     Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
     Lancet. 2021;398:1581-1592.
     

     >> Share

     
     April 2021
104. LOIBL S, Poortmans P, Morrow M, Denkert C, et al
     Breast cancer.
     Lancet. 2021 Apr 1. pii: S0140-6736(20)32381.
     

     >> Share

     
     March 2021
105. WANG C, Li A, Shi Q, Yu Z, et al
     Metagenomic next-generation sequencing clinches diagnosis of leishmaniasis.
     Lancet. 2021;397:1213.
     

     >> Share

     
     January 2021
106. 
     Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
     Lancet. 2021;397:387-397.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share